Facebook
Instagram
Pinterest
Reddit
Tumblr
X
Youtube
Home
About
News
Events
Shop
Directory
Contact Us
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Password recovery
Recover your password
your email
A password will be e-mailed to you.
PsyNews.com
Home
About
News
Events
Shop
Directory
Contact Us
Home
Featured
Page 224
Featured
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks Pricing; Potential LSD, Psilocybin Brand Names
Kenneth Tupper, PhD: Harm Reduction, Drug Education, Canadian Ayahuasca, and Psychedelic Public Health
Weekly Psychedelic Policy Briefing: October 5, 2026
Podcast: Oregon Backtracks on Fee Hike, California Funds Psychedelic Research, DEA Moves to Schedule 5 Tryptamines
Psychedelic Churches Need Psychedelic Seminaries
Editor’s Choice Award 2021-Best Study on Psychedelics and Pharmacology
MindMed Engages in Productive Pre-Submission Meeting with FDA for Development of...
Cybin Confirms Scientific Advice Meeting with UK Medical and Healthcare Products...
Delix Therapeutics Partners with the National Institute on Drug Abuse (NIDA)...
Psilera Confirms PSIL-002, A New DMT Derivative, is Well-Tolerated and Non-Hallucinogenic...
Editor’s Choice Award 2021-Best Study on Psychedelics and Nature
PT276 – Micah Haskell-Hoehl – Healing, Equity, and Federal Policy
Psychedelic Bulletin: MAPS’ $70m Investment Vehicle; atai’s Increased Stake in COMPASS;...
Psychiatrist and Addiction Researcher, Dr. Henry Kranzler Joins Entheon Advisory Board
Psyched Wellness Presents AME-1 to Health Canada in Pre-Submission Meeting
Load more